Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 18, 2008The Journal of Clinical Pharmacology

The Effect of Age and Gender on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase

View Full Paper
Ask AI
Bookmark
Share

Authors

RKReza KhosravanMKMichael KukulkaJWJingtao Wu

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Khosravan et al. (2008) studied this question.

synapsesocial.com/papers/6a71398df44fa9f079df0268https://doi.org/10.1177/0091270008322035
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Incidence and Risk Factors for Gout in White Men1991 · 238 citations
  2. 2Pharmacokinetics and Pharmacodynamics of Febuxostat, a New Non-purine Selective Inhibitor of Xanthine Oxidase in Subjects with Renal Impairment2005 · 156 citations
  3. 3The Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase2006 · 81 citations
  4. 4Febuxostat (TMX‐67), a Novel, Non‐Purine, Selective Inhibitor of Xanthine Oxidase, Is Safe and Decreases Serum Urate in Healthy Volunteers2004 · 96 citations